undamentalytics Newsletter
Sign in

Aptevo Therapeutics Inc. (APVO) stock

Add to watchlist

Add holding +

NASDAQ: APVO Nasdaq Biotechnology Next results ~November 5, 2026

Aptevo Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds2 adding, 2 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Current signal Net margin expanding: TTM net margin reached 257.8%, up 489.3pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 37.9% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 74.7% over the last 12 months.
  • Growth slowing. The growth rate is 36.3 points lower than a quarter earlier.
  • Loss-making. Operating margin is -919.7%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 745.7 points on a year ago.
  • Burning cash. Free cash flow was -704.0% of revenue over the last 12 months.

Latest results: FY2022 Q4

Filed March 5, 2024
Earnings per share
-$5.31 against an average estimate of -$6.20: beat by 14.3%
Share reaction
-17.4% in the first session after the results on August 14, 2026, against -0.7% for the S&P 500

Aptevo Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.5%
  • 1 week+3.9%
  • 1 month-24.4%
  • This year-85.7%
  • 1 year-95.0%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 14, 2026
Next results (est.)
November 5, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Agreement
  4. Announcement
  5. Announcement
  6. Shareholder vote
  7. Announcement
  8. Shareholder vote
  9. Results
  10. Agreement
  11. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Aptevo Therapeutics Inc. valuation models and calculator

No model value for Aptevo Therapeutics Inc. at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

8 /100

Weak moat

How hard Aptevo Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -90.7% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -224.0%; its worst year was -919.7%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -188.1% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 195130.8% over five years; stock-based pay has been a median 13.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$16.02 +82% — 0%
Next −$10.40 +35% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −33.6% on 90 days ago. In the last 30 days, 0 analysts raised Aptevo Therapeutics Inc.'s forecast and 1 cut it.

Consensus EPS forecast Aptevo Therapeutics Inc., last 90 days
−$30.00 −$20.00 −$10.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$24.13 Current fiscal year, 60 days ago: −$24.13 Current fiscal year, 30 days ago: −$24.13 Current fiscal year, 7 days ago: −$16.02 Current fiscal year, Now: −$16.02 −$16.02 Next fiscal year, 90 days ago: −$21.46 Next fiscal year, 60 days ago: −$21.46 Next fiscal year, 30 days ago: −$21.46 Next fiscal year, 7 days ago: −$10.40 Next fiscal year, Now: −$10.40 −$10.40

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$24.13−$21.46
60 days ago −$24.13−$21.46
30 days ago −$24.13−$21.46
7 days ago −$16.02−$10.40
Now −$16.02−$10.40

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$6.20 −$5.31 +14.3%
Mar 2026 −$5.60 −$6.41 −14.5%
Sept 2025 −$37.62 −$40.14 −6.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611

Counts of recommendations published by analysts covering Aptevo Therapeutics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.2%
of tradable shares
Days to cover
1.6
at average volume
Short interest, 1 month
−49%
to October 15, 2026
Held by institutions
3%
of shares
Held by insiders
4.2%
of shares
Employees
33
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
APVO−79%−71%−92%−99%−99%−86%
Industry peers (median)−35%−56%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
APVO0%33%0%42%17%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
APVO−84%−76%−93%−99%−100%−87%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since July 20, 2016: 100% from July 20, 2016 to October 27, 2026. Getting back needed a 5128199903% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.28 – $28.08
From 52-week high
−95.2%
vs 50-day average
−26.1%
vs 200-day average
−68.8%
Volatility (1 year)
91%
Beta vs S&P 500
0.99

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±8.0%
After a week
2 up, 10 down
typical move ±14.5%
After a month
1 up, 11 down
typical move ±28.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 14, 2026 −17.4% −0.7% −21.2% −49.7%
May 13, 2026 −0.7% +1.4% −5.7% −1.0%
March 26, 2026 −3.5% −3.5% −5.8% +11.2%
November 6, 2025 +2.8% −1.0% +1.4% −6.3%
August 11, 2025 −8.8% +0.9% −8.4% −33.6%
May 15, 2025 −3.0% +1.1% −9.1% −44.5%
April 28, 2025 −16.1% +0.7% −34.8% −65.9%
February 14, 2025 −4.1% +0.3% −11.8% −27.2%
November 7, 2024 +7.4% +1.2% −6.6% −8.5%
August 8, 2024 −10.1% +2.8% +4.6% −16.1%
May 8, 2024 −19.4% +0.6% −30.3% −31.8%
March 5, 2024 +2.4% −0.5% −34.9% −44.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Aptevo Therapeutics Inc.
$0 $10M $20M $30M $40M FY19 Q1 FY19 Q4 FY21 Q3 FY22 Q4 Revenue (TTM), FY19 Q1: $26M Revenue (TTM), FY19 Q2: $26.6M Revenue (TTM), FY19 Q3: $29.7M Revenue (TTM), FY19 Q4: $32.4M Revenue (TTM), FY21 Q1: $6.7M Revenue (TTM), FY21 Q2: $9.4M Revenue (TTM), FY21 Q3: $11M Revenue (TTM), FY21 Q4: $12.3M Revenue (TTM), FY22 Q1: $13M Revenue (TTM), FY22 Q2: $9.9M Revenue (TTM), FY22 Q3: $6.8M Revenue (TTM), FY22 Q4: $3.1M $3.1M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY19 Q1 $26M
FY19 Q2 $26.6M
FY19 Q3 $29.7M
FY19 Q4 $32.4M
FY21 Q1 $6.7M
FY21 Q2 $9.4M
FY21 Q3 $11M
FY21 Q4 $12.3M
FY22 Q1 $13M
FY22 Q2 $9.9M
FY22 Q3 $6.8M
FY22 Q4 $3.1M
Revenue growth, TTM YoY Aptevo Therapeutics Inc.
-100% -50% 0% 50% 100% FY18 Q1 FY18 Q4 FY19 Q3 FY22 Q4 Revenue growth, TTM YoY, FY18 Q1: -0.4% Revenue growth, TTM YoY, FY18 Q2: -18.8% Revenue growth, TTM YoY, FY18 Q3: -29.8% Revenue growth, TTM YoY, FY18 Q4: 5.3% Revenue growth, TTM YoY, FY19 Q1: 9.2% Revenue growth, TTM YoY, FY19 Q2: 33.5% Revenue growth, TTM YoY, FY19 Q3: 52.2% Revenue growth, TTM YoY, FY19 Q4: 40.6% Revenue growth, TTM YoY, FY22 Q1: 92.9% Revenue growth, TTM YoY, FY22 Q2: 5.4% Revenue growth, TTM YoY, FY22 Q3: -38.4% Revenue growth, TTM YoY, FY22 Q4: -74.7% -74.7%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY18 Q1 -0.4%
FY18 Q2 -18.8%
FY18 Q3 -29.8%
FY18 Q4 5.3%
FY19 Q1 9.2%
FY19 Q2 33.5%
FY19 Q3 52.2%
FY19 Q4 40.6%
FY22 Q1 92.9%
FY22 Q2 5.4%
FY22 Q3 -38.4%
FY22 Q4 -74.7%
Operating margin (TTM) Aptevo Therapeutics Inc.
-1000% -500% 0% FY19 Q1 FY19 Q4 FY21 Q3 FY22 Q4 Operating margin (TTM), FY19 Q1: -190.6% Operating margin (TTM), FY19 Q2: -188.5% Operating margin (TTM), FY19 Q3: -166.1% Operating margin (TTM), FY19 Q4: -134.9% Operating margin (TTM), FY21 Q1: -397.6% Operating margin (TTM), FY21 Q2: -274.1% Operating margin (TTM), FY21 Q3: -219.8% Operating margin (TTM), FY21 Q4: -174.1% Operating margin (TTM), FY22 Q1: -155.0% Operating margin (TTM), FY22 Q2: -222.4% Operating margin (TTM), FY22 Q3: -368.7% Operating margin (TTM), FY22 Q4: -919.7% -919.7%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY19 Q1 -190.6%
FY19 Q2 -188.5%
FY19 Q3 -166.1%
FY19 Q4 -134.9%
FY21 Q1 -397.6%
FY21 Q2 -274.1%
FY21 Q3 -219.8%
FY21 Q4 -174.1%
FY22 Q1 -155.0%
FY22 Q2 -222.4%
FY22 Q3 -368.7%
FY22 Q4 -919.7%
FCF margin (TTM) Aptevo Therapeutics Inc.
-800% -600% -400% -200% 0% FY18 Q2 FY19 Q1 FY19 Q4 FY22 Q4 FCF margin (TTM), FY18 Q2: -256.5% FCF margin (TTM), FY18 Q3: -311.0% FCF margin (TTM), FY18 Q4: -227.2% FCF margin (TTM), FY19 Q1: -188.1% FCF margin (TTM), FY19 Q2: -183.5% FCF margin (TTM), FY19 Q3: -150.6% FCF margin (TTM), FY19 Q4: -131.2% FCF margin (TTM), FY21 Q4: -182.2% FCF margin (TTM), FY22 Q1: -157.0% FCF margin (TTM), FY22 Q2: -186.1% FCF margin (TTM), FY22 Q3: -294.4% FCF margin (TTM), FY22 Q4: -704.0% -704.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY18 Q2 -256.5%
FY18 Q3 -311.0%
FY18 Q4 -227.2%
FY19 Q1 -188.1%
FY19 Q2 -183.5%
FY19 Q3 -150.6%
FY19 Q4 -131.2%
FY21 Q4 -182.2%
FY22 Q1 -157.0%
FY22 Q2 -186.1%
FY22 Q3 -294.4%
FY22 Q4 -704.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022
Income
Revenue 34 10 15 23 32 4 12 3
Gross profit — — — 12 12 — — —
EBITDA −58 −135 −51 −49 −39 −26 −20 −28
Operating income −61 −139 −54 −52 −41 −27 −21 −29
Net income −59 −112 7 −54 −40 −18 −28 8
Diluted EPS −$14767.20 −$5.55 $0.33 −$2.39 −$13.86 −$5.23 −$6.07 $1.57
Growth (year on year)
Revenue — −70.3% +46.8% +57.4% +40.6% −86.7% +185.3% −74.7%
Net income — — — −870.0% — — — —
Diluted EPS — — — −824.2% — — — —
Margins
Gross margin — — — 51.4% 38.5% — — —
EBITDA margin −173.2% <−999% −346.7% −213.6% −119.4% −605.4% −164.8% −890.8%
Operating margin −181.8% <−999% −368.1% −224.0% −126.3% −638.1% −174.1% −919.7%
Net margin −176.5% <−999% 47.6% −232.8% −124.7% −411.9% −231.5% 257.8%
Free-cash-flow margin −149.7% −394.3% −293.2% −227.2% −131.2% −682.4% −182.2% −676.0%
Cash flow
Cash from operations −49 −37 −42 −51 −42 −29 −22 −21
Capital spending 2 3 1 1 0 0 1 0
Free cash flow −50 −39 −43 −52 −43 −29 −22 −21
Stock-based pay 1 4 5 2 2 1 2 2
Free cash flow after stock pay −51 −43 −48 −55 −44 −31 −24 −23
Balance sheet
Cash 5 10 7 31 12 40 45 23
Total debt 0 18 19 19 39 28 16 4
Net debt (negative = net cash) −5 9 12 −11 27 −12 −29 −19
Diluted shares — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated APVO UPB XBIO ALGS DYAI DBVT Median
Revenue, last 12 months $3m $3m $3m $4m $4m $4m $55m
Revenue growth, last 12 months −74.7% 16.0% 33.3% 19.4% −8.0% −31.6% 12.2%
Revenue growth, 3-year average −48.7% — 14.7% −5.5% 3.4% −11.6% 13.1%
Revenue growth, latest quarter −100.0% −17.5% 12.0% −100.0% −0.6% −42.9% 10.2%
Gross margin 38.5% — 99.8% — 16.2% — 82.8%
Operating margin −919.7% <−999% −81.0% <−999% −195.1% <−999% −191.1%
Operating margin, 3-year average −409.6% <−999% −137.7% <−999% −257.9% <−999% −365.3%
Net margin 257.8% <−999% −75.9% <−999% −200.5% <−999% −163.5%
Cash from operations / revenue −675.1% <−999% −70.9% <−999% −194.7% <−999% −168.8%
Free-cash-flow margin −704.0% <−999% −70.9% <−999% — <−999% −168.1%
Free-cash-flow margin, 3-year average −358.1% — −103.3% <−999% — <−999% −313.4%
Stock pay / revenue 57.8% 446.5% 2.9% 149.8% 17.1% 335.9% 20.7%
Change in share count −37.9% — 34.7% 30.7% 20.3% 216.3% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$224,344
Institutions reporting
9
Shares held vs prior quarter
▼ 6.1%
Positions opened / closed
1 / 0

Top buyers and sellers, Q2 2026: 2 institutions bought and 2 sold ; the biggest buyer was Gsa Capital Partners LLP (+1,901 shares) and the biggest seller UBS Group AG (−2,715). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Gsa Capital Partners LLP $96,000 22K 42.8% ▲ 9.7%
Vanguard Capital Management LLC $56,446 13K 25.2% 0.0%
Geode Capital Management, LLC $48,044 11K 21.4% ▼ 18.9%
Vanguard Fiduciary Trust Co $18,390 4K 8.2% 0.0%
UBS Group AG $3,242 1K 1.4% ▼ 78.8%
Osaic Holdings, Inc. $1,596 0K 0.7% 0.0%
Sbi Securities Co., Ltd. $484 0K 0.2% 0.0%
Barclays PLC $138 0K 0.1% New
Danske Bank A/S $4 0K 0.0% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Aptevo Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $20,134 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $20,134 net buying
Insider Date Trade Shares Price Value
Grant Grady Iii Director November 10, 2025 Buy 13,513 $1.49 $20,134

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Aptevo Therapeutics Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Steve Cohen(D-TN 9):Sale (full), $470.99, traded June 24, 2019, filed July 3, 2019

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 14, 2026
  • May 13, 2026
  • March 26, 2026
  • November 6, 2025
  • August 11, 2025
  • May 15, 2025

Recent SEC filings

Data status

When each part of this page on Aptevo Therapeutics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Aptevo Therapeutics Inc. in brief

What does Aptevo Therapeutics Inc. do?
Aptevo Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Aptevo Therapeutics Inc.'s stock ticker?
Aptevo Therapeutics Inc. trades under the ticker APVO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Aptevo Therapeutics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Gsa Capital Partners LLP, Vanguard Capital Management LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Aptevo Therapeutics Inc.'s market cap?
On December 30, 2022, Aptevo Therapeutics Inc.'s market capitalisation was about $19.3B, with a price-to-earnings ratio of 2401.1 and net debt of -$18.6M. Market figures come from third-party market data and may be delayed.
Who are Aptevo Therapeutics Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Aptevo Therapeutics Inc. are Upstream Bio, Inc., Xenetic Biosciences, Inc., Aligos Therapeutics, Inc., Dyadic International Inc and DBV Technologies S.a. The side-by-side comparison below sets their revenue, margins and growth against Aptevo Therapeutics Inc.'s.
Are insiders buying or selling Aptevo Therapeutics Inc. stock?
Over the last 12 months, Aptevo Therapeutics Inc.'s directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Aptevo Therapeutics Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Aptevo Therapeutics Inc. announces its own schedule.